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A B S T R A C T
Antiplatelet drugs constitute the cornerstone therapy in acute coronary syndromes 
(ACS) and patients undergoing percutaneous coronary intervention (PCI). Aspirin 
is part of the standard treatment given to these patients, further supplemented by 
clopidogrel, which both significantly reduce the short- and long-term risk of death 
and ischemic complications in high-risk settings. However, the pharmacokinetic and 
pharmacodynamic effects of clopidogrel are highly variable and may be influenced 
by genetic polymorphisms, which lead to reduced therapeutic responses and clopi-
dogrel “nonresponders”. Two newer oral adenosine diphosphate blockers, prasugrel 
and ticagrelor, have already entered clinical practice, associated with less interpatient 
variability and a more potent antiplatelet effect. In recent studies, both prasugrel and 
ticagrelor were shown to be superior to clopidogrel in patients with ACS who were 
undergoing PCI; based on the results of these studies, cardiological societies have re-
cently updated their guidelines and have included these agents into their recommen-
dations. In this review, these newer oral antiplatelet agents, their effects and clinical 
results are discussed, together with the preliminary results of another new intravenous 
antiplatelet agent, cangrelor, which can bridge the discontinuation of the oral agents 
up to the time of surgery when needed.
I N T R O D U C T I O N
Platelet activation and subsequent aggregation play a dominant role in the propa-
gation of arterial thrombosis and consequently are the key therapeutic targets in the 
management of acute coronary syndrome (ACS). Platelets can be activated through 
many pathways. Inhibition of such a pathway results only in partial attenuation of 
platelet function. Aspirin irreversibly blocks platelet cyclooxygenase (COX-1), inhibits 
thromboxane A2 formation and induces a permanent functional inhibition in plate-
lets. As a consequence, aspirin use has been shown to safely reduce ischemic events 
throughout the spectrum of clinical manifestations of coronary artery disease (CAD). 
Therefore, aspirin is part of the standard treatment given to patients with CAD, includ-
ing those undergoing percutaneous coronary intervention (PCI).1,2
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Despite the inhibition of cyclooxygenase by aspirin, platelet 
activation can still occur through thromboxane-independent 
pathways, leading to aggregation of platelets and formation 
of thrombin. Thus, inhibition of an additional pathway of 
platelet activation could further reduce platelet activity. 
As a consequence, the antagonists of P2Y12 receptor have 
emerged as a major therapeutic tool in ACS.1,2 Clopidogrel, 
an oral P2Y12 receptor inhibitor, added to standard regimen 
with aspirin further reduces the short- and long-term risk 
of death and ischemic complications in high-risk settings, 
such as patients with an ACS and those undergoing PCI.1,3-8 
However, the pharmacokinetic and pharmacodynamic effects 
of clopidogrel are highly variable and may be influenced by 
genetic polymorphisms, which translate into differential 
pharmacodynamics and therapeutic responses,2,9-15 leading 
to the notion of clopidogrel “nonresponders”.16 Two newer 
oral adenosine diphosphate (ADP) blockers, prasugrel and 
ticagrelor, have been associated with less interpatient vari-
ability and a more potent platelet-aggregation response.13-15,17 
Prasugrel was superior to clopidogrel in patients with ACS 
who were undergoing PCI,18-21 and ticagrelor was superior to 
clopidogrel in patients with ACS.22-25
Thus, dual antiplatelet therapy (DAPT) with aspirin and 
an oral P2Y12 receptor inhibitor is the standard of care to 
prevent the short- and long-term risk of recurrent athero-
thrombotic events in high-risk settings, such as patients with 
an ACS and those undergoing PCI.1,26-29 However, the ischemic 
benefit associated with more intense platelet inhibition in these 
high-risk settings occurs at the expense of an increased risk 
of bleeding complications.26-29 Given that the risk of bleeding 
is significantly increased among patients undergoing surgical 
procedures, discontinuation of antiplatelet therapy for a time 
frame that allows recovery of platelet function is warranted. 
However, premature discontinuation of antiplatelet therapy in 
these settings has been associated with an increase in ischemic 
complications30-33 and substantial morbidity and mortality.34-37 
These findings underscore the need to define strategies of 
platelet inhibition that allow to safely “bridge” patients to their 
surgical procedure with minimum risk of ischemic events or 
bleeding complications. Cangrelor, a nonthienopyridine intra-
venous (IV) antagonist of the P2Y12 receptor, is characterized 
by rapid, potent, predictable, and reversible platelet inhibition 
with rapid offset of effect.1,13,38 Therefore, this compound 
has desirable pharmacodynamic properties to be considered 
for bridging patients to surgery in whom discontinuation of 
antiplatelet therapy, particularly a P2Y12 receptor inhibitor, 
can lead to adverse consequences (e.g., stent thrombosis) 
while preserving normal hemostasis at the time of surgery.39 
According to the BRIDGE study, cangrelor could represent 
a safe and effective drug for bridging patients treated with 
irreversible platelet P2Y12 inhibitors such as clopidogrel to 
coronary artery bypass grafting (CABG) surgery.40
P R A S U G R E L
Prasugrel is a newer thienopyridine, binding irreversibly 
to platelet P2Y12 receptors. Like ticlopidine and clopidogrel, 
prasugrel is a prodrug that is inactive in vitro.41 Prasugrel 
requires two metabolic steps for formation of its active me-
tabolite, which is chemically similar to the active metabolite 
of clopidogrel.14 The first metabolic step requires only plasma 
esterases; the second step, in the liver, is mediated by CYP en-
zymes. Finally, more than 80% of the dose received by mouth 
is converted to the active metabolite. In contrast, clopidogrel 
is extensively hydrolysed by esterases to inactive metabolites 
(by 85% – 90%), and the residual prodrug requires two meta-
bolic steps in the liver for formation of its active metabolite. 
Eventually, only ~2% of a single dose received by mouth is 
detected on the platelet P2Y12 receptors. As a consequence, 
while equimolar concentrations of the active metabolites of 
clopidogrel and prasugrel result in similar levels of platelet 
inhibition in vitro, the markedly different amounts of each 
metabolite generated in vivo following a loading dose of 
clopidogrel (300 mg) or prasugrel (60 mg) result in ~10-fold 
higher platelet exposure to the latter when compared with the 
former.41 This observation provides a pharmacokinetic basis 
for the faster, more profound and less variable inhibition of 
platelet function observed with prasugrel when compared 
with clopidogrel in healthy subjects41 as well as in patients 
with ischemic heart disease.18-21,42,43 Moreover, in contrast to 
clopidogrel, the lack of drug interaction potential and the 
apparent independence of CYP2C19 genetic variance and of 
reduced ABCB1 function result in a predictable and consistent 
antiplatelet response to prasugrel.42-44
Prasugrel was compared with clopidogrel in the TRITON-
TIMI 38 trial.18 The study included 13,608 clopidogrel-naïve 
patients with moderate-to-high-risk ACS undergoing PCI. 
Cases treated conservatively were not included in this study. 
Patients were randomly assigned to receive, in addition to 
aspirin, prasugrel (a 60-mg loading dose and a 10-mg daily 
maintenance dose) or clopidogrel (a 300-mg loading dose 
and a 75-mg daily maintenance dose) for 6 to 15 months. The 
primary efficacy end-point was death from cardiovascular 
causes, nonfatal myocardial infarction (MI), or nonfatal stroke. 
The key safety end-point was major bleeding. In the whole 
cohort, prasugrel therapy for 6 to 15 months was associated 
with a significantly lower rate of the primary efficacy end-point 
(9.9% for prasugrel vs. 12.1% for clopidogrel; HR 0.81; 95% 
CI: 0.73 – 0.90; P <0.001), mostly driven by a significant risk 
reduction for MI (7.4% vs. 9.7%; HR 0.76; 95% CI: 0.67 – 0.85; 
P <0.001). It is noteworthy that this beneficial effect of prasu-
grel appeared very early by the first prespecified time point, at 
3 days (4.7 vs. 5.6%; HR 0.82; 95% CI: 0.71 – 0.96; P = 0.01), 
and persisted throughout the follow-up period. Moreover, 
from 3 days to the end of the study, there was a progressive 
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benefit increase in favor of prasugrel (5.6% vs. 6.9%; HR 0.80; 
95% CI: 0.70 – 0.93; P = 0.003). Also lower in the prasugrel 
group was the rate of definite or probable stent thrombosis 
(1.1% vs. 2.4%; HR 0.48; 95% CI: 0.36 – 0.64; P <0.001), as 
well as the rate of urgent target-vessel revascularization (2.5% 
vs. 3.7%; P < 0.001). There was no difference in the rates of 
either non-fatal stroke or cardiovascular death. With regards 
to the safety end-point, there was a significant increase in 
the rate of non-CABG-related TIMI major bleeding among 
patients receiving prasugrel (2.4% vs. 1.8%;HR 1.32; 95% CI: 
1.03 – 1.68; P = 0.03), mostly driven by a significant increase 
in spontaneous bleeds (1.6% vs. 1.1%; HR 1.51; 95% CI: 1.09 
– 2.08; P = 0.01), but not by bleeding related to arterial ac-
cess (0.7% vs. 0.6%; HR 1.18; 95% CI: 0.77 – 1.82; P = 0.45), 
which means that long-term exposure to a potent antiplatelet 
agent is the determinant of bleeding. Life-threatening bleed-
ing was also significantly increased under prasugrel (1.4% vs. 
0.9%; HR 1.52; 95% CI: 1.08 – 2.13; P = 0.01), as well as fatal 
bleeding with prasugrel compared with clopidogrel (0.4% vs. 
0.1%; HR 4.19; 95% CI: 1.58 – 11.11; P = 0.002). Significantly 
more frequent was also bleeding in total (HR 1.31; 95% CI: 
1.11 – 1.56; P = 0.002), bleeding requiring transfusion (HR 
1.34; 95% CI: 1.11 – 1.63; P <0.001), and TIMI major bleeding 
related to CABG (HR 4.73; 95% CI: 1.90 – 11.82; P <0.001).
Prespecified as well as post hoc subgroup analyses in 
TRITON-TIMI 38 trial identified subgroups of interest that 
had different clinical efficacy and absolute levels of bleeding 
than the overall cohort, resulting in less or greater net clinical 
benefit or clinical harm.18 Accordingly, there was evidence of 
net harm with prasugrel in patients with a history of cerebro-
vascular events. In addition, there was no apparent net clinical 
benefit in patients >75 years of age and in patients with low 
body weight (<60 kg). Greater benefit without increased risk 
of bleeding was observed in diabetic patients. There was no 
difference in efficacy in patients with (CrCl <60 mL/min) or 
without (CrCl >60 mL/min) renal impairment. Although re-
duction in the rate of ischemic events by means of more than 
one antiplatelet agent has uniformly been accompanied by an 
increase in bleeding, a benefit with prasugrel with regard to the 
primary end-point was found both with the use of glycoprotein 
IIb/IIIa-receptor antagonists during the index hospitalization 
(HR for prasugrel vs. clopidogrel, 0.79; 95% CI: 0.69 – 0.91; 
P<0.001) or without such use (HR 0.84; 95% CI: 0.72 – 0.99; 
P = 0.03). Moreover, the beneficial effects of prasugrel with 
regard to ischemic outcomes and stent thrombosis, as com-
pared to clopidogrel, were statistically robust irrespective of 
stent type,19 and these data affirm the importance of intensive 
platelet inhibition in patients with intracoronary stents.
In the NSTE-ACS sub-cohort of the TRITON-TIMI 38 
trial (10,074 patients), the composite primary efficacy end-
point rate was also lower among patients receiving prasugrel 
(9.3% vs. 11.2%; HR 0.82; 95% CI: 0.73 – 0.93; P = 0.002), 
mostly driven by a significant risk reduction for MI (from 
9.2% to 7.1%; RRR 23.9%; 95% CI: 12.7 – 33.7; P < 0.001), 
as it was in the whole cohort. There was no difference in 
the rates of either non-fatal stroke or cardiovascular death. 
Bleeding risks were along with those in the whole cohort of 
the TRITON-TIMI 38 trial.18 Figures for stent thrombosis rate 
for NSTE-ACS patients, however, are not available.
In the STEMI sub-cohort of the TRITON-TIMI 38 trial 
(3,534 patients),20 benefits of prasugrel therapy appeared very 
early. At 30 days, prasugrel therapy was associated with a sig-
nificantly lower incidence of the composite primary efficacy 
end-point (6.5% vs. 9.5%; HR 0.68; 95% CI: 0.54 – 0.87; P = 
0.0017; NNT 35), MI (4.9% vs. 7.0%; HR 0.70; 95% CI: 0.53 – 
0.92; P = 0.0106; NNT 49), and stent thrombosis (2.4% 1.2%; 
HR 0.49; 95% CI: 0.28 – 0.84; P = 0.0084; NNT 81) without 
significant increase in the incidence of non-CABG-related 
TIMI major bleeding (1.3% vs. 1.0%; HR 0.74; 95% CI: 0.39 
– 1.38; P = 0.3359). Also, there was no difference in the rates 
of either non-fatal stroke or cardiovascular death. All these 
beneficial effects persisted unchangeable for 15 months. This 
finding was consistent with that in the population with unsta-
ble angina or non-STEMI, with no interaction noted between 
presenting syndrome and benefits of prasugrel (p = 0.7686). 
With regards to the safety, treatment with either prasugrel or 
clopidogrel did not differ with respect to non-CABG-related 
TIMI major bleeding at 30 days (P = 0.3359) and at 15 months 
(P = 0.6451). TIMI life-threatening bleeding and TIMI major 
or minor bleeding were also similar with the two treatment 
regimens, and only TIMI major bleeding after CABG surgery 
was significantly increased with prasugrel (P = 0.0033).
A small retrospective observational substudy of the TRI-
TON-TIMI 38 trial involved 346 patients who had received 
either study drug and subsequently underwent isolated CABG 
at some point during the 15-month trial.21 In spite of an in-
creased risk of bleeding, patients treated with prasugrel prior 
to isolated CABG were observed to have significantly lower 
mortality compared to patients who received clopidogrel prior 
to CABG while enrolled in the TRITON-TIMI 38 study. It is 
noteworthy that almost all patients were back on their study 
drug within a week of surgery. However, these results must 
be interpreted with caution because the analysis consisted of 
small numbers.
TRITON-TIMI 38 trial tested prasugrel vs. clopidogrel in 
intermediate-to-high-risk patients with ACS undergoing PCI 
and demonstrated a significant benefit of prasugrel in reducing 
ischemic events, but with an increased risk of bleeding. Given 
this favorable result in ACS patients undergoing stenting, 
TRIGGER-PCI trial45 attempted to compare prasugrel and 
clopidogrel in lower risk patients, as those with stable coronary 
artery disease who had just undergone elective PCI. Although 
the study was based on platelet-reactivity testing to guide an-
tiplatelet therapy in this otherwise low-risk PCI population, 
it was prematurely halted due to futility. The ongoing TRIL-
OGY ACS trial,46 inspired predominantly from (a) trials which 
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demonstrated that clopidogrel added to aspirin was superior to 
aspirin alone to reduce ischemic events in ACS patients treated 
medically3,6,8 and (b) the TRITON-TIMI 38 trial which showed 
the superiority of prasugrel over clopidogrel,18 compares 
prasugrel and clopidogrel in exclusively medically managed 
NSTE ACS patients and will provide important information 
regarding the optimal approach to oral antiplatelet therapy 
for this high-risk, understudied population.
Except for bleeding, the rate of other adverse effects 
in TRITON-TIMI 38 study was similar to that of prasugrel 
and clopidogrel. Thrombocytopenia occurred at the same 
frequency in each group (0.3%) while neutropenia was less 
common with prasugrel (<0.1% vs. 0.2%; P = 0.02).
C O N C L U S I O N
Prasugrel provides faster, more profound and less variable 
inhibition of platelet function than clopidogrel. Prasugrel, in 
contrast to clopidogrel, results in predictable and consistent 
antiplatelet response. In ACS patients with scheduled PCI, 
prasugrel therapy is associated with significantly reduced 
rates of ischemic events, MI, and stent thrombosis, but with 
an increased risk of major bleeding, including fatal bleeding, 
and no benefit with regard to overall mortality. However, in 
STEMI patients undergoing PCI, the beneficial effects of 
prasugrel on the prevention of ischemic events, MI, and stent 
thrombosis are not associated with apparent excess in bleeding. 
To date, the superiority of prasugrel over clopidogrel has been 
demonstrated only in the setting of ACS patients undergoing 
PCI with stent implantation.
T I C A G R E L O R
Ticagrelor belongs to a novel chemical class, cyclopentyl-
triazolopyrimidine, and is a reversible and direct-acting oral 
antagonist of the ADP receptor P2Y12 with a plasma half-life 
of ~12 h. The level of P2Y12 inhibition is determined by the 
plasma ticagrelor level and, to a lesser extent, an active me-
tabolite. Like prasugrel, it provides faster, greater and more 
consistent P2Y12 inhibition than clopidogrel, but additionally it 
has a quicker offset of action so that recovery of platelet func-
tion is faster (functional recovery of circulating platelets within 
~48 hours). Notably, its action begins in the portal circulation 
immediately after intestine absorption in contrast to clopi-
dogrel and prasugrel of which the inhibitory action begins in 
the systemic circulation after an enzymatic biotransformation 
in the liver. Ticagrelor increases levels of drugs metabolized 
through CYP3A, such as simvastatin, whilst moderate CYP3A 
inhibitors such as diltiazem increase the levels and reduce the 
speed of offset of the effect of ticagrelor.1,13,17,28
PLATO, a randomized, double-blind trial, compared 
ticagrelor with clopidogrel for the prevention of vascular events 
in 18 624 ACS patients.22 The study included patients with 
either moderate-to-high-risk NSTE-ACS (planned for either 
conservative or invasive management) or STEMI (planned 
for primary PCI). A substantial difference from the TRITON-
TIMI 38 trial, which included only patients with ACSs treated 
exclusively with PCI, was the induction of patients with any 
ACS planned for invasive management and patients with 
NSTE-ACS planned only for medical management. Patients 
were randomly assigned to receive, in addition to aspirin, 
ticagrelor or clopidogrel. The treatment was continued for 6 
to 15 months (median duration of study drug exposure of 9 
months). The primary efficacy end-point was a composite of 
death from cardiovascular causes, nonfatal MI, or nonfatal 
stroke. The key safety end-point was major bleeding. In the 
overall cohort, ticagrelor therapy for 6 to 15 months was associ-
ated with a significantly lower rate of the primary composite 
efficacy end-point (9.8% vs. 11.7%; HR 0.84; 95% CI: 0.77 
– 0.92; P <0.001), MI (5.8% vs. 6.9%; HR 0.84; 95% CI: 0.75 
– 0.95; P = 0.005), definite stent thrombosis (1.3% vs. 1.9%; P 
<0.01), total mortality (4.5% vs. 5.9%; P < 0.001), and death 
from vascular causes (4.0% vs. 5.1%; HR 0.79; 95% CI: 0.69 
– 0.91; P = 0.001). While reduction in stent thrombosis rates 
by ticagrelor were seen early, most of the benefit in terms of 
reduced MI and death occurred progressively over 12 months, 
with continued separation of event curves at 12 months. It is 
noteworthy that these benefits were observed mainly among 
patients with increased troponin levels. Indeed, those patients 
with a positive initial troponin had a significant reduction in the 
primary endpoint with ticagrelor compared with clopidogrel 
(10.3% vs. 12.3%, HR 0.85; 95% CI: 0.77 – 0.94) in contrast 
to patients with negative initial troponin (7.0% vs. 7.0%), as 
did those with a final diagnosis of NSTEMI (11.4% vs. 13.9%; 
HR 0.83; 95% CI: 0.73 – 0.94) compared with those with a 
final diagnosis of unstable angina (8.6% vs. 9.1% respectively; 
HR 0.96; 95% CI: 0.75 – 1.22). Regarding safety, treatment 
with ticagrelor and clopidogrel did not differ significantly with 
respect to rate of stroke (1.5% vs. 1.3%; P = 0.22) and overall 
PLATO-defined major bleeding (11.6% vs. 11.2%; P = 0.43) at 
the end of follow-up. However, though major bleeding related 
to CABG surgery was similar with the two treatments (7.4% 
vs. 7.9%; P = 0.32), non-CABG-related major bleeding was 
significantly increased with ticagrelor (4.5% vs. 3.8%; HR 1.19; 
95% CI: 1.02 – 1.38; P = 0.03). Minor bleeding was likewise 
increased with ticagrelor compared with clopidogrel. There 
was no difference in the overall rates of fatal hemorrhage 
between the groups (0.3% in both groups). However, intrac-
ranial fatal hemorrhage was more frequent in the ticagrelor 
group (0.1% vs. 0.01%; P = 0.02) while non-intracranial fatal 
hemorrhage was more frequent in the clopidogrel group (0.1% 
vs. 0.3%; P = 0.03).
In the PLATO trial, 1261 patients underwent CABG while 
were on study drug treatment for <7 days before surgery.23 
As per protocol, ticagrelor or clopidogrel could be restarted 
when it was considered safe in terms of bleeding and be con-
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tinued up to 12th month of study. In this subgroup of patients 
undergoing CABG within 7 days after the last study drug 
intake, ticagrelor compared with clopidogrel was associated 
with a substantial reduction in the primary composite efficacy 
end-point (10.6% vs. 13.1%; HR 0.84; 95% CI: 0.60 – 1.16; 
P = 0.29), total mortality (4.7% vs. 9.7%; HR 0.49; 95% CI: 
0.32 – 0.77; P < 0.01), and cardiovascular mortality (4.1% vs. 
7.9%; HR 0.52; 95% CI: 0.32 – 0.85; P < 0.01) without excess 
risk of CABG-related bleeding. Non-cardiovascular mortality 
was also numerically lower in the ticagrelor group (0.7% vs. 
2.0%; P = 0.07). Interestingly, the above benefit with respect 
to the reduced mortality with ticagrelor appeared early within 
the first month and continued accruing progressively during the 
rest of the follow-up period. Thus, in post-ACS patients who 
will need CABG at any time during dual antiplatelet treatment, 
ticagrelor as compared with clopidogrel reduces early and 
late cardiovascular and total death following CABG without 
an increase in major bleeding. Given that the post-operative 
administration of clopidogrel in patients who undergo CABG 
within 180 days after MI has been associated with reduced 
total and cardiovascular mortality,47 the above results are of 
great importance.
In patients with STEMI intended for reperfusion with 
primary PCI (N = 7,544), the effects of ticagrelor compared 
with clopidogrel were consistent with those seen in the overall 
PLATO trial.24 Ticagrelor produced a consistent reduction in 
the primary composite efficacy end-point, cardiovascular and 
total death, MI, and stent thrombosis and improved survival 
without increasing major bleeding but with a higher rate of 
stroke. The absolute mortality reduction from ticagrelor over 
clopidogrel was of the same magnitude as that achieved with 
tissue plasminogen activator compared with streptokinase48 but 
without the corresponding increase in intracranial bleeding and 
with a reduction in reinfarction not seen with thrombolysis. 
Furthermore, these benefits are obtained compared with ac-
tive treatment with clopidogrel and on top of aspirin, primary 
PCI, and other evidence-based secondary prevention therapies 
widely used in PLATO patients.
In the context of PLATO trial, an early invasive strategy 
was planned at the time of randomization in 13,408 (72%) of 
18,624 patients hospitalized for ACS, either STEMI (49.1%) or 
NSTE-ACS (50.9%).25 PCI was carried out in 10,298 (76.8%) 
individuals, and CABG in 782 (5.8%) during first hospital ad-
mission. In this subgroup of patients intended for reperfusion 
with an early invasive strategy, patients given ticagrelor had 
significant reductions in primary and secondary composite ef-
ficacy end-point, cardiovascular and total deaths, MI, and stent 
thrombosis, without an increase in the risk of major bleeding 
or transfusion. The benefit of ticagrelor vs. clopidogrel for the 
composite primary efficacy end-point of cardiovascular death, 
myocardial infarction, or stroke was similar across a wide range 
of subgroups, irrespective of the loading dose of clopidogrel. 
In general, the benefits with respect to clinical events and 
stent thrombosis were consistent whether or not patients were 
given standard or higher loading doses of clopidogrel, as ad-
vocated for patients undergoing invasive strategies. However, 
the benefits of ticagrelor were most evident among patients 
with increased cardiac troponin, and the mortality benefit of 
ticagrelor was more notable in patients with non-STE-ACSs. It 
is estimated that the use of ticagrelor instead of clopidogrel for 
1 year in 1000 patients with ACS and who are planned to un-
dergo an invasive strategy at the start of drug treatment would 
lead to 11 fewer deaths, 13 fewer myocardial infarctions, and 6 
fewer cases of stent thrombosis without an increase in the rates 
of major bleeding or transfusion. These results also support 
the idea that increased inhibition of platelet P2Y12 receptors 
in the setting of an invasive management of ACS can achieve 
substantial reduction in the rate of mortality when not associ-
ated with an increase in the rate of major bleeding. Thereby, 
ticagrelor has important advantages, and improves the early 
invasive and long-term management of patients with ACS. 
Regarding the adverse effects, in addition to increased 
rates of minor or non-CABG-related major bleeding, therapy 
with ticagrelor may induce dyspnea, increased frequency 
of ventricular pauses, and asymptomatic increases in uric 
acid.22,47,50 Dyspnea induced by ticagrelor occurs most fre-
quently (up to 15%) within the first week of treatment and 
may be transient or persist until cessation of treatment, but 
only infrequently it is severe enough to cause discontinuation 
of treatment.22,51 Dyspnea does not appear to be associated 
with any deterioration in cardiac or pulmonary function.51 
Ventricular pauses associated with ticagrelor mostly consist of 
asymptomatic nocturnal sinoatrial pauses; caution is advised in 
patients with either advanced sinoatrial disease or second- or 
third-degree atrioventricular block, unless already treated by 
permanent pacemaker. The mechanism for the dyspnea and 
ventricular pauses is uncertain. A slightly greater increase in 
serum creatinine was seen in the PLATO trial with ticagrelor 
compared with clopidogrel, but the difference was no longer 
apparent 1 month after cessation of treatment.22 Rates of gas-
trointestinal disturbance and rash are similar with ticagrelor 
compared with clopidogrel.50
C O N C L U S I O N
Ticagrelor compared with clopidogrel provides faster, 
more profound and less variable inhibition of platelet function 
and results in predictable and consistent antiplatelet response. 
The above characteristics represent a profile similar to that 
of prasugrel, but additionally ticagrelor has a quicker offset 
of action so that recovery of platelet function theoretically is 
faster, within 2 – 3 days instead of >7 days for prasugrel. How-
ever, current recommendations advise that, like clopidogrel, 
ticagrelor should also be stopped 5 days before surgery. In pa-
tients who have an ACS with or without ST-segment elevation, 
ticagrelor therapy compared to that of clopidogrel significantly 
reduces the rate of overall major ischemic events, cardiovas-
NEW ANTI-THROMBOTIC DRUGS IN ACS AND PCI. THE ROLE OF PRASUGREL, TICAGRELOR AND CANGRELOR
49
cular death, all-cause mortality, MI, and stent thrombosis and 
improves survival without increasing overall major bleeding 
but with a higher rate of non–procedure-related bleeding, in-
cluding more instances of fatal intracranial bleeding and fewer 
of fatal bleeding of other types. The benefit of ticagrelor vs. 
clopidogrel with respect to reduction of major cardiovascular 
events is similar across a wide range of subgroups regardless 
of the loading dose of clopidogrel and regardless of whether 
invasive or noninvasive management is planned. In addition, 
the survival benefit from more-intense platelet inhibition with 
ticagrelor in patients with ACS is consistent with reductions in 
the mortality rate obtained by means of platelet inhibition with 
aspirin in patients with ACS52,53 and with clopidogrel in patients 
with STEMI.54 It is noteworthy that all these benefits are ob-
served mainly among patients with increased troponin levels. 
Furthermore, the beneficial effect of ticagrelor compared to 
that of clopidogrel is seen early and continues accruing pro-
gressively over time, with continued separation of event curves 
at 12 months. This duration of treatment benefit has also been 
shown with clopidogrel.55 Thus, ticagrelor appears to expand on 
the previously demonstrated benefits of clopidogrel across the 
spectrum of ACS. Moreover, the incremental reduction in the 
risk of coronary thrombotic events in ACS patients undergoing 
PCI through more-intense P2Y12 inhibition with ticagrelor 
is consistent with similar effects of prasugrel.18 However, the 
most impressive distinction of ticagrelor from the other two 
oral potent inhibitors of P2Y12 receptors is a robust reduc-
tion of the rate of death that appears early and then continues 
increasing over time, effects not seen with clopidogrel or 
prasugrel. This advantage of ticagrelor over clopidogrel in 
terms of reduced mortality is similar in magnitude to other 
major advances, such as streptokinase or aspirin vs. placebo,56 
tissue plasminogen activator vs. streptokinase,48 and primary 
PCI vs. tissue plasminogen activator,57 in care of patients 
with STEMI. However, the mortality benefit with ticagrelor 
is more notable in patients with non-STE-ACS treated with 
PCI, particularly those with an increase in cardiac troponin, 
when previous antithrombotic treatments were unsuccessful in 
improving survival by a reduction in ischemic events.2,18,53,58-61 
These findings show that, compared with the benefits noted 
with clopidogrel vs. placebo, additional protection from is-
chemic events can be achieved with ticagrelor.
C A N G R E L O R
Withholding P2Y12 inhibitors because of the risk for 
bleeding in the case of a necessary or mandatory non-coronary 
cardiac or non-cardiac surgical procedure or in the case of 
an imminent CABG surgery may lead to an increased rate 
of thrombotic events. Interruption of DAPT soon after stent 
implantation or after initiation of DAPT for the management 
of ACS, specifically in high risk cohorts such as those with 
ongoing ischemia in presence of high risk coronary anatomy, 
increases excessively the risk of coronary thrombotic complica-
tions, which carries a particularly adverse prognosis.30-37 As the 
overall periprocedural time window of withdrawal of a P2Y12 
inhibitor is major determinant of the consequent coronary 
thrombosis as well as the ensuing bleeding,26,35 the advent of 
a P2Y12 receptor inhibitor characterized by rapid, potent, 
predictable, and reversible platelet inhibition with very rapid 
offset of effect might be of great value for patients in whom 
discontinuation of antiplatelet therapy, particularly a P2Y12 
receptor inhibitor, can lead to adverse consequences while 
preserving normal hemostasis at the time of surgery.1,2,39,62
Cangrelor, a nonthienopyridine adenosine triphosphate 
analogue, is an IV administered direct-acting, selective, and 
specific P2Y12 inhibitor. It is characterized by rapid, potent, 
predictable, and reversible platelet inhibition with very rapid 
offset of its effect.13,38,63 In particular, cangrelor is metabolized 
through dephosphorylation pathways and has a plasma half-
life of 3 to 6 minutes. When given as a bolus plus infusion, 
quickly and consistently inhibits platelets to a high degree, 
with normalization of platelet function within 30 to 60 minutes 
after discontinuation.63 Moreover, cangrelor has an additional 
antiplatelet effect when added in vitro to the platelets of pa-
tients receiving long-term treatment with clopidogrel.64,65 A 
phase 2 trial involving patients undergoing PCI showed dose-
dependent platelet inhibition similar to that of abciximab (a 
IIB/IIIa antagonist), less prolongation of bleeding time, and 
a more rapid return to platelet function.66 Therefore, this 
compound might have a role in the treatment of patients who 
require rapid, predictable, and profound but very fast reverse 
of platelet inhibition.
Cangrelor has been studied in two large, phase 3, rand-
omized clinical trials. Interestingly, both studies were stopped 
when an interim analysis concluded that the trials would be 
unlikely to show superiority for the primary end point. CHAM-
PION PLATFORM trial67 examined the efficacy of cangrelor 
vs. placebo administered to NSTE-ACS patients during PCI, 
with patients in the placebo group subsequently receiving a 
loading dose of 600 mg of clopidogrel at the end of the revas-
cularization procedure and patients in the cangrelor group 
receiving 600 mg of clopidogrel at the end of the infusion, at 
least 2 hours after PCI. The primary efficacy end point was a 
composite of death from any cause, MI, or ischemia-driven 
revascularization at 48 hours. In this trial, the use of peripro-
cedural cangrelor during PCI was not superior to placebo in 
reducing the composite primary end point. However, in the 
cangrelor group, as compared with the placebo group, two 
prespecified secondary end points were significantly reduced at 
48 hours. Indeed, the rate of stent thrombosis was significantly 
lower in the cangrelor group (0.2% vs. 0.6%; odds ratio-OR 
0.31; 95% CI: 0.11 – 0.85; P = 0.02) and the difference was 
still significant at 30 days. Likewise, the rate of death from 
any cause was significantly lower in the cangrelor group (0.2% 
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vs. 0.7%; OR 0.33; 95% CI: 0.13 – 0.83; P = 0.02), though at 
30 days, this difference was no longer significant. Given the 
rapid effect on platelet inhibition seen in the CHAMPION 
platelet substudy, these reductions in stent thrombosis and 
death are biologically plausible. With regards to safety, there 
was no significant difference in the rate of blood transfusion 
(P = 0.13), though major bleeding on one scale was increased 
in the cangrelor group (5.5% vs. 3.5%; P<0.001) because of 
more groin hematomas.
CHAMPION PCI trial68 compared IV cangrelor with 600 
mg of oral clopidogrel administered before PCI in patients with 
ACS. Cangrelor was administered IV 30 minutes before PCI 
and continued for at least 2 hours after PCI, with patients in the 
cangrelor group subsequently receiving a loading dose of 600 
mg of clopidogrel at the end of the infusion. An oral loading 
dose of 600 mg of clopidogrel was given 30 minutes before PCI 
in the patients of the clopidogrel group. The primary efficacy 
end point was a composite of death from any cause, MI, or 
ischemia-driven revascularization at 48 hours. In this trial, 
IV cangrelor was not superior to a 600-mg loading dose of 
clopidogrel, administered 30 minutes before PCI, in reducing 
the composite primary efficacy end point (7.5% vs. 7.1%; OR 
1.05; 95% CI: 0.88 – 1.24; P = 0.59). Likewise, cangrelor was 
not superior at 30 days. Minor bleeding was more common in 
patients who received cangrelor, and one measure of major 
bleeding (based on criteria from the ACUITY trial69) showed 
a trend toward an increase in bleeding with cangrelor as com-
pared with clopidogrel. In addition, a secondary exploratory 
end point of death from any cause, Q-wave MI, or ischemia-
driven revascularization showed a trend toward a reduction 
with cangrelor, but it was not significant (0.6% vs. 0.9%; OR 
0.67; 95% CI: 0.39 – 1.14; P = 0.14).
The BRIDGE trial40 evaluated the hypothesis that cangre-
lor may be a safe and effective drug to bridge patients from 
irreversible platelet P2Y12 inhibitors to open heart surgery. 
The trial involved 210 patients with an ACS or treated with a 
coronary stent and receiving a thienopyridine, awaiting CABG 
surgery. Thienopyridines were stopped and patients were 
administered cangrelor or placebo for the thienopyridine-free 
time frame (for at least 48 hours). Study drug was discontinued 
1 to 6 hours before CABG surgery and was not administered 
during or after CABG surgery. The primary efficacy end 
point was platelet reactivity (measured in P2Y12 reaction 
units [PRUs]), assessed daily. Specifically, the aim was to 
assess whether a cangrelor IV infusion would maintain levels 
of platelet reactivity of less than 240 PRUs throughout the 
preoperative period as measured by the VerifyNow P2Y12 
assay. Of note, such a level of platelet reactivity is known to 
be associated with a low risk of thrombotic events. This level 
approximated the levels of platelet reactivity expected to be 
maintained if a thienopyridine had not been discontinued.70,71 
The main safety end point was excessive CABG surgery-
related bleeding. In this trial, it was shown that the proportion 
of patients with low levels of platelet reactivity throughout 
the entire treatment period was significantly greater in the 
cagrelor group than in the placebo group (98.8% vs. 19.0%; 
RR 5.2 [95% C: 3.3 – 8.1]; P < 0.001). The rates of excessive 
CABG-related bleeding were similar between the two groups 
(11.8% vs. 10.4%; RR 1.1 [95% CI: 0.5 – 2.5] P = 0.763). In 
addition, bridging with a prolonged infusion of cangrelor did 
not increase major bleeding prior to CABG surgery, although 
minor bleeding episodes were numerically higher with can-
grelor. Thus, in this trial, cangrelor achieved and maintained 
target levels of platelet inhibition known to be associated 
with a low risk of thrombotic events compared with placebo, 
without a significant excess in bleeding complications. The 
trial was not planned and not powered to show differences in 
ischemic events. Of note, this hypothesis had previously been 
tested in the CHAMPION PCI trial.68 This trial showed that 
treatments with cagrelor and clopidogrel did not differ with 
respect to the primary end-point of death from any cause, MI, 
or ischemia-driven revascularization at 48 hours.68
C O N C L U S I O N
Cangrelor, a nonthienopyridine ATP analogue, is an IV 
administered direct-acting, selective, and specific P2Y12 re-
ceptor inhibitor characterized by rapid, potent, predictable, 
and reversible platelet inhibition with very rapid offset of its 
effect. However, the most important clinically relevant char-
acteristic of cagrelor is the very fast offset of its antiplatelet 
effect, with normalization of platelet function within 30 to 
60 minutes after discontinuation. Therefore, this compound 
might have a role in the treatment of patients who require 
rapid, predictable, and profound but very fast reverse of 
platelet inhibition. Indeed, among patients who discontinue 
thienopyridine therapy prior to cardiac surgery, the prolonged 
infusion of cangrelor throughout the thienopyridine-free time 
frame maintains an effective therapeutic level of platelet inhi-
bition without an increase in major bleeding prior to CABG or 
excessive CABG-related bleeding.40 Regarding the efficacy of 
cangrelor administered to NSTE-ACS patients during PCI, the 
CHAMPION PLATFORM trial failed to show any benefit in 
terms of reducing death, MI, or ischemia-driven revasculari-
zation at 48 hours. Despite this negative result, however, the 
rates of stent thrombosis and death were reduced very early, 
within the first 48 hours, with no significant increase in bleed-
ing, except for groin hematomas.67 Given the rapid effect on 
platelet inhibition seen in the CHAMPION platelet substudy, 
these reductions in stent thrombosis and death are biologically 
plausible, and might be of value in the clinical setting. With 
regards to the comparison of cangrelor with clopidogrel in 
the setting of patients with ACS undergoing PCI, it has been 
shown that periprocedural IV cangrelor was not superior to a 
600-mg loading dose of clopidogrel, administered 30 minutes 
before PCI, in reducing the composite end point of death from 
any cause, myocardial infarction, or ischemia-driven revascu-
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larization at 48 hours.68 To date, the most meaningful result 
from the clinical trials of cangrelor is that IV cangrelor is a 
feasible management strategy in patients waiting for cardiac 
surgery who require prolonged platelet P2Y12 inhibition after 
thienopyridine discontinuation.
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